Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
November 9, 2022
Manufacturing files submitted to U.S. Food and Drug Administration The company has now completed its transition to U.S.-based manufacturing NRX-101 is now manufactured via a commercial-stage...
-
November 7, 2022
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in...
-
September 8, 2022Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting...
-
August 22, 2022Release of an ad hoc announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (OTCQB: RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), today announced that they have agreed to a tentative...
-
August 15, 2022Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022...
-
August 10, 2022
In the news release, NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022, issued Aug. 10, 2022 by NRx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company...
-
July 13, 2022
Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential...
-
July 1, 2022Focus is now on NRX-101 for Bipolar Depression with Suicidality
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue...
-
June 23, 2022Company to Present Corporate and Psychiatry Franchise Update During Webcast, June 27, 2022, at 7:00am ET
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other...
-
June 22, 2022
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, the plaintiffs in the securities class...
Click here to view our corporate presentation or on the image below